Pacific Biosciences of California Dirección

Dirección controles de criterios 2/4

El CEO de Pacific Biosciences of California's es Christian O. Henry , nombrado en Sep 2020, tiene una permanencia de 3.58 años. compensación anual total es $6.62M, compuesta por 10.1% salario y 89.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $440.84K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 11.2 años, respectivamente.

Información clave

Christian O. Henry

Chief Executive Officer (CEO)

US$6.6m

Compensación total

Porcentaje del salario del CEO	10.1%
Permanencia del CEO	3.6yrs
Participación del CEO	0.1%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	11.2yrs

Actualizaciones recientes de la dirección

Recent updates

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26

Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Aug 08

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

Jul 27

Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Jul 11

Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong

Apr 05

Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?

Feb 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Christian O. Henry en comparación con los beneficios de Pacific Biosciences of California?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$307m
Sep 30 2023	n/a	n/a	-US$309m
Jun 30 2023	n/a	n/a	-US$319m
Mar 31 2023	n/a	n/a	-US$321m
Dec 31 2022	US$7m	US$667k	-US$314m
Sep 30 2022	n/a	n/a	-US$299m
Jun 30 2022	n/a	n/a	-US$206m
Mar 31 2022	n/a	n/a	-US$175m
Dec 31 2021	US$3m	US$650k	-US$181m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$59m
Dec 31 2020	US$13m	US$195k	US$29m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$51m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$100k	n/a	-US$84m
Sep 30 2019	n/a	n/a	-US$115m
Jun 30 2019	n/a	n/a	-US$111m
Mar 31 2019	n/a	n/a	-US$109m
Dec 31 2018	US$88k	n/a	-US$103m

Compensación vs. Mercado: La compensación total de Christian O.($USD6.62M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Christian O. ha aumentado mientras la empresa no es rentable.

CEO

Christian O. Henry (55 yo)

3.6yrs

Permanencia

US$6,616,251

Compensación

Mr. Christian O. Henry, MBA, serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He has been President and Chief Executive Officer at Pacific Biosciences of California, Inc. S...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian O. Henry	President	3.6yrs	US$6.62m	0.11% $ 413.8k
Susan Kim	Chief Financial Officer	3.6yrs	US$2.62m	0.036% $ 134.3k
Mark Van Oene	Chief Operating Officer	3.3yrs	US$6.56m	0.10% $ 385.6k
Jeff Eidel	Chief Commercial Officer	1.7yrs	US$5.80m	0.032% $ 120.1k
Stephen Turner	Co-Founder	23.8yrs	US$466.76k	sin datos
Michele Farmer	VP & Chief Accounting Officer	2.9yrs	sin datos	0.012% $ 43.5k
Trevin Rard	Head of Investor Relations	no data	sin datos	sin datos
Brett Atkins	General Counsel & Corporate Secretary	no data	sin datos	sin datos
Natalie Welch	Chief People Officer	no data	sin datos	sin datos
Denis Zaccarin	Senior Vice President of Research & Development	less than a year	US$1.48m	sin datos
Mike Goloubef	Senior Vice President of Manufacturing & Quality	no data	sin datos	sin datos
Benjamin Gong	VP of Finance & Treasurer	13.9yrs	sin datos	sin datos

3.4yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PACB se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian O. Henry	President	5.8yrs	US$6.62m	0.11% $ 413.8k
William Ericson	Independent Director	20.3yrs	US$259.00k	0.0069% $ 25.9k
Lucy Shapiro	Independent Director	11.6yrs	US$255.00k	0% $ 0
John Milligan	Independent Chairman	10.8yrs	US$297.00k	0.040% $ 151.8k
Harry Gray	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Joseph Bonventre	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Randall Livingston	Independent Director	15.3yrs	US$265.00k	0% $ 0
Harold Craighead	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Roger Kornberg	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Watt Webb	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Kenneth Johnson	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Jay Shendure	Chairman of Scientific Advisory Board	1.4yrs	sin datos	sin datos

11.2yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de PACB son experimentados ( 11.2 años antigüedad media).

Pacific Biosciences of California Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insider recently bought US$176k worth of stock

President recently sold US$481k worth of stock

President notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Recent updates

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

New major risk - Share price stability

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Price target decreased by 11% to US$9.41

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought US$176k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

President recently sold US$481k worth of stock

President notifies of intention to sell stock

Price target decreased by 9.2% to US$11.17

Full year 2023 earnings: EPS misses analyst expectations

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold US$241k worth of stock

Price target decreased by 7.7% to US$11.92

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Price target decreased by 7.3% to US$12.67

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Price target decreased by 10% to US$13.92

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold US$980k worth of stock

President notifies of intention to sell stock

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Chief Operating Officer recently sold US$287k worth of stock

Chief Operating Officer notifies of intention to sell stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Price target increased by 8.6% to US$14.73

Now 20% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Now 24% undervalued

VP & Chief Accounting Officer recently sold US$65k worth of stock

Price target increased by 9.1% to US$13.50

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Independent Director notifies of intention to sell stock

President notifies of intention to sell stock

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Full year 2022 earnings: EPS misses analyst expectations

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing